Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Acquisitions & Divestments for 10 consecutive years, with $82.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 55583.78% to $82.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $444.0 million, a 14700.0% increase, with the full-year FY2025 number at $444.0 million, up 14700.0% from a year prior.
  • Change in Acquisitions & Divestments was $82.1 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $135.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $648.5 million in Q4 2023 to a low of -$359.7 million in Q3 2023.
  • A 5-year average of $115.6 million and a median of $85.8 million in 2025 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 362.81% in 2022, then skyrocketed 55583.78% in 2025.
  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments stood at $134.1 million in 2021, then tumbled by 68.1% to $42.8 million in 2022, then soared by 1415.85% to $648.5 million in 2023, then plummeted by 100.02% to -$148000.0 in 2024, then surged by 55583.78% to $82.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Acquisitions & Divestments are $82.1 million (Q4 2025), $135.6 million (Q3 2025), and $89.4 million (Q2 2025).